Recurrent lymphangiomyomatosis after transplantation

Genetic analyses reveal a metastatic mechanism

Magdalena Karbowniczek, Aristotelis Astreinidis, Binaifer R. Balsara, Joseph R. Testa, James H. Lium, Thomas V. Colby, Francis X. McCormack, Elizabeth Petri Henske

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Lymphangiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells and cystic degeneration of the lung. LAM affects almost exclusively young women. Although lung transplantation provides effective therapy for end-stage LAM, there are reports of LAM recurrence after lung transplantation. Whether these recurrent LAM cells arise from the patient or the lung transplant donor is an area of controversy. We used microsatellite marker fingerprinting and TSC2 gene mutational analysis to study a patient with recurrent LAM after single-lung transplantation. The DNA microsatellite marker pattern indicated the presence of patient-derived LAM cells in the allograft. A somatic one base pair deletion in exon 18 of the TSC2 gene was identified in pulmonary and lymph node LAM cells before transplantation. The same mutation was in the recurrent LAM, demonstrating that the recurrent LAM was derived from the patient. Fluorescence in situ hybridization revealed that cells immunoreactive with the monoclonal antibody HMB-45 did not contain a Y chromosome. These data indicate that histologically benign LAM cells can migrate or metastasize in vivo to the transplanted lung. In addition, the patient had no evidence of a renal angiomyolipoma at autopsy and therefore demonstrated for the first time that somatic TSC2 mutations cause LAM in patients without angiomyolipomas.

Original languageEnglish (US)
Pages (from-to)976-982
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume167
Issue number7
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Lymphangioleiomyomatosis
Transplantation
Lung Transplantation
Angiomyolipoma
Lung
Microsatellite Repeats
Mutation
Y Chromosome
Cell Transplantation
Fluorescence In Situ Hybridization
Genetic Markers
Base Pairing
Genes
Smooth Muscle Myocytes
Allografts

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Recurrent lymphangiomyomatosis after transplantation : Genetic analyses reveal a metastatic mechanism. / Karbowniczek, Magdalena; Astreinidis, Aristotelis; Balsara, Binaifer R.; Testa, Joseph R.; Lium, James H.; Colby, Thomas V.; McCormack, Francis X.; Henske, Elizabeth Petri.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 167, No. 7, 01.04.2003, p. 976-982.

Research output: Contribution to journalArticle

Karbowniczek, Magdalena ; Astreinidis, Aristotelis ; Balsara, Binaifer R. ; Testa, Joseph R. ; Lium, James H. ; Colby, Thomas V. ; McCormack, Francis X. ; Henske, Elizabeth Petri. / Recurrent lymphangiomyomatosis after transplantation : Genetic analyses reveal a metastatic mechanism. In: American Journal of Respiratory and Critical Care Medicine. 2003 ; Vol. 167, No. 7. pp. 976-982.
@article{2e335e436da240c59e42bd66945e0a00,
title = "Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism",
abstract = "Lymphangiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells and cystic degeneration of the lung. LAM affects almost exclusively young women. Although lung transplantation provides effective therapy for end-stage LAM, there are reports of LAM recurrence after lung transplantation. Whether these recurrent LAM cells arise from the patient or the lung transplant donor is an area of controversy. We used microsatellite marker fingerprinting and TSC2 gene mutational analysis to study a patient with recurrent LAM after single-lung transplantation. The DNA microsatellite marker pattern indicated the presence of patient-derived LAM cells in the allograft. A somatic one base pair deletion in exon 18 of the TSC2 gene was identified in pulmonary and lymph node LAM cells before transplantation. The same mutation was in the recurrent LAM, demonstrating that the recurrent LAM was derived from the patient. Fluorescence in situ hybridization revealed that cells immunoreactive with the monoclonal antibody HMB-45 did not contain a Y chromosome. These data indicate that histologically benign LAM cells can migrate or metastasize in vivo to the transplanted lung. In addition, the patient had no evidence of a renal angiomyolipoma at autopsy and therefore demonstrated for the first time that somatic TSC2 mutations cause LAM in patients without angiomyolipomas.",
author = "Magdalena Karbowniczek and Aristotelis Astreinidis and Balsara, {Binaifer R.} and Testa, {Joseph R.} and Lium, {James H.} and Colby, {Thomas V.} and McCormack, {Francis X.} and Henske, {Elizabeth Petri}",
year = "2003",
month = "4",
day = "1",
doi = "10.1164/rccm.200208-969OC",
language = "English (US)",
volume = "167",
pages = "976--982",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "7",

}

TY - JOUR

T1 - Recurrent lymphangiomyomatosis after transplantation

T2 - Genetic analyses reveal a metastatic mechanism

AU - Karbowniczek, Magdalena

AU - Astreinidis, Aristotelis

AU - Balsara, Binaifer R.

AU - Testa, Joseph R.

AU - Lium, James H.

AU - Colby, Thomas V.

AU - McCormack, Francis X.

AU - Henske, Elizabeth Petri

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Lymphangiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells and cystic degeneration of the lung. LAM affects almost exclusively young women. Although lung transplantation provides effective therapy for end-stage LAM, there are reports of LAM recurrence after lung transplantation. Whether these recurrent LAM cells arise from the patient or the lung transplant donor is an area of controversy. We used microsatellite marker fingerprinting and TSC2 gene mutational analysis to study a patient with recurrent LAM after single-lung transplantation. The DNA microsatellite marker pattern indicated the presence of patient-derived LAM cells in the allograft. A somatic one base pair deletion in exon 18 of the TSC2 gene was identified in pulmonary and lymph node LAM cells before transplantation. The same mutation was in the recurrent LAM, demonstrating that the recurrent LAM was derived from the patient. Fluorescence in situ hybridization revealed that cells immunoreactive with the monoclonal antibody HMB-45 did not contain a Y chromosome. These data indicate that histologically benign LAM cells can migrate or metastasize in vivo to the transplanted lung. In addition, the patient had no evidence of a renal angiomyolipoma at autopsy and therefore demonstrated for the first time that somatic TSC2 mutations cause LAM in patients without angiomyolipomas.

AB - Lymphangiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells and cystic degeneration of the lung. LAM affects almost exclusively young women. Although lung transplantation provides effective therapy for end-stage LAM, there are reports of LAM recurrence after lung transplantation. Whether these recurrent LAM cells arise from the patient or the lung transplant donor is an area of controversy. We used microsatellite marker fingerprinting and TSC2 gene mutational analysis to study a patient with recurrent LAM after single-lung transplantation. The DNA microsatellite marker pattern indicated the presence of patient-derived LAM cells in the allograft. A somatic one base pair deletion in exon 18 of the TSC2 gene was identified in pulmonary and lymph node LAM cells before transplantation. The same mutation was in the recurrent LAM, demonstrating that the recurrent LAM was derived from the patient. Fluorescence in situ hybridization revealed that cells immunoreactive with the monoclonal antibody HMB-45 did not contain a Y chromosome. These data indicate that histologically benign LAM cells can migrate or metastasize in vivo to the transplanted lung. In addition, the patient had no evidence of a renal angiomyolipoma at autopsy and therefore demonstrated for the first time that somatic TSC2 mutations cause LAM in patients without angiomyolipomas.

UR - http://www.scopus.com/inward/record.url?scp=0345237920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345237920&partnerID=8YFLogxK

U2 - 10.1164/rccm.200208-969OC

DO - 10.1164/rccm.200208-969OC

M3 - Article

VL - 167

SP - 976

EP - 982

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 7

ER -